Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Primary Completion Date

February 28, 2005

Study Completion Date

February 28, 2005

Conditions

Carcinoma, Non-Small-Cell LungLung Neoplasms

Interventions

DRUG

MAC-321

Trial Locations (13)

New York

Pittsburgh

Philadelphia

Charlotte

Charleston

Nashville

Cleveland

Minneapolis

St Louis

Los Angeles

Lexington

Baltimore

Worcester

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00063219 - Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy | Biotech Hunter | Biotech Hunter